SE390818B - Sett att framstella klatratforeningar av prostaglandiner med cyklodextrin - Google Patents

Sett att framstella klatratforeningar av prostaglandiner med cyklodextrin

Info

Publication number
SE390818B
SE390818B SE7107486A SE748671A SE390818B SE 390818 B SE390818 B SE 390818B SE 7107486 A SE7107486 A SE 7107486A SE 748671 A SE748671 A SE 748671A SE 390818 B SE390818 B SE 390818B
Authority
SE
Sweden
Prior art keywords
cyclodextrine
prostaglandins
climate
preparing
compounds
Prior art date
Application number
SE7107486A
Other languages
English (en)
Swedish (sv)
Inventor
M Hayashi
A Ishihara
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of SE390818B publication Critical patent/SE390818B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0025—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing keto groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE7107486A 1970-06-10 1971-06-09 Sett att framstella klatratforeningar av prostaglandiner med cyklodextrin SE390818B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP45050119A JPS503362B1 (xx) 1970-06-10 1970-06-10

Publications (1)

Publication Number Publication Date
SE390818B true SE390818B (sv) 1977-01-24

Family

ID=12850213

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7107486A SE390818B (sv) 1970-06-10 1971-06-09 Sett att framstella klatratforeningar av prostaglandiner med cyklodextrin

Country Status (22)

Country Link
US (1) US3816393A (xx)
JP (1) JPS503362B1 (xx)
AT (1) AT332570B (xx)
BE (1) BE768288A (xx)
CA (1) CA958007A (xx)
CH (1) CH568259A5 (xx)
CS (1) CS170169B2 (xx)
CY (1) CY895A (xx)
DE (1) DE2128674C2 (xx)
DK (1) DK140837B (xx)
ES (1) ES392074A1 (xx)
FR (1) FR2100745B1 (xx)
GB (1) GB1351238A (xx)
HK (1) HK17577A (xx)
HU (1) HU163135B (xx)
IE (1) IE35326B1 (xx)
NL (1) NL162901C (xx)
NO (1) NO134373C (xx)
RO (1) RO62182A (xx)
SE (1) SE390818B (xx)
SU (1) SU404225A3 (xx)
ZA (1) ZA713398B (xx)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4163108A (en) * 1967-02-16 1979-07-31 Lever Brothers Company Prostaglandins
US4054736A (en) * 1970-06-10 1977-10-18 Ono Pharmaceutical Co., Ltd. Clathrate compounds of prostaglandins or their analogues with cyclodextrin
US3954833A (en) * 1971-04-12 1976-05-04 The Upjohn Company 16,16-Methyl and ethyl substituted PGF2.sub.α compounds
CA984387A (en) * 1971-04-12 1976-02-24 Barney J. Magerlein Analogs of prostaglandins
US3903131A (en) * 1971-04-12 1975-09-02 Upjohn Co 16 and 16,16-dimethyl PGE{HD 2{B
FR2134673A1 (en) * 1971-04-30 1972-12-08 Ono Pharmaceutical Co Novel optically active isomers of prostaglandin analoguesof natural configuration useful as hypotensive agents, diuretics,contraceptives, for treating gastric ulcer and asthma, and forinhibiting platelet aggregation
US4045467A (en) * 1972-02-18 1977-08-30 May & Baker Limited Cyclopentane derivatives
US4082789A (en) * 1972-03-28 1978-04-04 The University Court Of The University Of Edinburgh Prostaglandins C2
JPS4926258A (xx) * 1972-07-06 1974-03-08
US4130721A (en) * 1972-07-24 1978-12-19 The Upjohn Company 11-Deoxy PGE2 compounds
US4110368A (en) * 1972-07-24 1978-08-29 American Cyanamid Company Hydro substituted prostanoic acids and esters
US4141914A (en) * 1972-07-24 1979-02-27 American Cyanamid Company Novel 11-deoxy-11-substituted prostaglandins of the E and F series
JPS4942648A (xx) * 1972-08-24 1974-04-22
US3962312A (en) * 1972-09-21 1976-06-08 Ono Pharmaceutical Company 9,11,15-Trihydroxy prost-5-enoic acid analogues
US3972917A (en) * 1972-10-27 1976-08-03 American Home Products Corporation 11-Deoxy 15-methyl prostaglandin E1
JPS5443570B2 (xx) * 1972-10-27 1979-12-20
US4092427A (en) * 1973-04-16 1978-05-30 American Home Products Corporation Method of inducing abortion using alkyl derivatives of prostanoic acids
JPS5623984B2 (xx) * 1973-04-19 1981-06-03
US4246426A (en) * 1973-08-06 1981-01-20 Hoffmann-La Roche Inc. 11-Substituted prostaglandins
US4059576A (en) * 1973-08-06 1977-11-22 Hoffmann-La Roche, Inc. 11-Substituted prostaglandins
US4052446A (en) * 1973-08-06 1977-10-04 Hoffmann-La Roche Inc. 11,16-substituted prostaglandins
US4026927A (en) * 1973-09-25 1977-05-31 Yamanouchi Pharmaceutical Co., Ltd. Novel prostaglandin derivatives
US4036954A (en) * 1973-11-02 1977-07-19 Yamanouchi Pharmaceutical Co., Ltd. Stable prostaglandin E group-containing formulation
GB1448268A (en) * 1973-11-13 1976-09-02 May & Baker Ltd Cyclopentane derivatives
GB1441564A (en) * 1974-02-07 1976-07-07 Upjohn Co Prostaglandins
US4041066A (en) * 1974-02-07 1977-08-09 The Upjohn Company 4,5-Cis-didehydro-PGE1 compounds
DE2416193C2 (de) * 1974-04-03 1985-08-14 Hoechst Ag, 6230 Frankfurt Prostaglandin-Analoge, Verfahren zu ihrer Herstellung sowie ihre Verwendung als cytoprotektives Mittel
US4256651A (en) * 1974-10-02 1981-03-17 The Upjohn Company 2a,2b-Dihomo-15-alkyl-PGF1β compounds
US3974195A (en) * 1974-10-02 1976-08-10 The Upjohn Company 2A,2B-Dihomo-15-alkyl-PGF2.sub.α analogs
GB1482010A (en) * 1974-10-28 1977-08-03 Ono Pharmaceutical Co Prostaglandin analogues
DK142235B (da) * 1974-12-20 1980-09-29 Yamanouchi Pharma Co Ltd Analogifremgangsmåde til fremstilling af 20-alkoxy-16-methyl-prostadiensyre-derivater.
US4207420A (en) * 1975-02-24 1980-06-10 The Upjohn Company 2,2-Difluoro-PGF1 analogs
US4209637A (en) * 1975-02-24 1980-06-24 The Upjohn Company 2,2-Difluoro-PGF2 analogs
US4059701A (en) * 1975-04-17 1977-11-22 American Home Products Corporation 15-Substituted prostanoic acids for treating bronchial spasm
FR2313019A2 (fr) * 1975-06-04 1976-12-31 Ono Pharmaceutical Co Nouveaux analogues de prostaglandines et leur procede de preparation
US4086269A (en) * 1975-07-07 1978-04-25 American Home Products Corporation 11-Deoxy-15-substituted prostaglandins
US4026909A (en) * 1975-07-14 1977-05-31 The Upjohn Company Cis-13-PGF2.sub.α analogs
US4016184A (en) * 1975-09-17 1977-04-05 The Upjohn Company 9-Deoxy-9,10-didehydro-PGD1 compounds
US4033989A (en) * 1975-09-17 1977-07-05 The Upjohn Company 9-Deoxy-PGF2 Analogs
US4013695A (en) * 1975-10-02 1977-03-22 The Upjohn Company 4,4,5,5-Tetradehydro-PGE1 analogs
US4053500A (en) * 1975-10-02 1977-10-11 The Upjohn Company 4,4,5,5-Tetradehydro-ω-aryl-PGF1α analogs
US4053502A (en) * 1975-10-02 1977-10-11 The Upjohn Company 4,4,5,5-Tetradehydro-ω-aryl-PGE1 analogs
US4026919A (en) * 1975-10-23 1977-05-31 The Upjohn Company PGD2 Substituted esters
US4058665A (en) * 1975-11-06 1977-11-15 Yamanouchi Pharmaceutical Co., Ltd. Novel 3,15-dilower alkyl PGE2 derivatives
US4212986A (en) * 1976-09-17 1980-07-15 The Upjohn Company 2,2-Difluoro-PGE2 analogs
US4212987A (en) * 1976-09-17 1980-07-15 The Upjohn Company 2,2-Difluoro-PGE1 analogs
US4169895A (en) * 1976-09-28 1979-10-02 Pfizer Inc. Antisecretory 16,16-dimethyl-17-oxaprostaglandins
JPS53136513A (en) * 1977-05-06 1978-11-29 Ono Pharmaceut Co Ltd Stabilization of prostaglandin-x-related compounds
HU179141B (xx) * 1977-09-23 1982-08-28
JPS5577440U (xx) * 1978-11-25 1980-05-28
US4244883A (en) * 1979-09-12 1981-01-13 The Upjohn Company 2a,2b-Dihomo-15-alkyl-PGF2β compounds
ZA831186B (en) * 1982-03-22 1983-11-30 Upjohn Ltd Gelled pge2/triacetin solutions
DE3504044A1 (de) * 1985-02-04 1986-08-07 Schering AG, Berlin und Bergkamen, 1000 Berlin 9-halogenprostaglandin-clathrate und ihre verwendung als arzneimittel
DE3608088C2 (de) * 1986-03-07 1995-11-16 Schering Ag Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten
DE3740838A1 (de) * 1987-11-27 1989-06-08 Schering Ag Cyclodextrinclathrate von 5-cyano-prostacyclinderivaten und ihre verwendung als arzneimittel
PT89301B (pt) * 1987-12-22 1995-07-03 Glaxo Group Ltd Processo para a preparacao de composicoes aquosas que contem um derivado do acido piperridinil-ciclo-pentil-heptenoico
US5221695A (en) * 1987-12-22 1993-06-22 Glaxo Group Limited Aqueous formulation containing a piperidinylcyclopentylheptenoic acid derivative and beta-cyclodextrin
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
DE19828881A1 (de) * 1998-06-22 1999-12-23 Schering Ag Oxidationsinhibitor bei Prostan-Derivaten
US6287603B1 (en) 1999-09-16 2001-09-11 Nestec S.A. Cyclodextrin flavor delivery systems
MXPA04000757A (es) 2001-07-23 2004-07-08 Ono Pharmaceutical Co Remedios para enfermedades con perdida de masa de hueso que tienen agonistas ep4 como ingrediente activo.
ES2393321T3 (es) 2002-10-10 2012-12-20 Ono Pharmaceutical Co., Ltd. Promotores de la producción de factores de reparación endógenos
US20070270489A1 (en) 2003-07-25 2007-11-22 Ono Pharmaceutical Co., Ltd. Remedy for Cartilage-Related Diseases
CN100542537C (zh) * 2004-07-27 2009-09-23 中国人民解放军军事医学科学院毒物药物研究所 前列腺素e1口腔制剂
WO2006137959A1 (en) * 2005-06-13 2006-12-28 Cargill, Incorporated Cyclodextrin inclusion complexes and methods of preparing same
CN101223182A (zh) * 2005-06-13 2008-07-16 嘉吉公司 环糊精包合复合物及其制备方法
WO2007145663A1 (en) * 2006-06-13 2007-12-21 Cargill, Incorporated Large-particle cyclodextrin inclusion complexes and methods of preparing same
US20100160623A1 (en) * 2006-12-27 2010-06-24 Cargill, Incorporated Cyclodextrin inclusion complexes and methods of preparing same
MX2009008606A (es) 2007-02-16 2009-09-16 Ono Pharmaceutical Co Agente terapeutico para trastorno de excrecion urinaria.
KR20100016299A (ko) 2007-05-08 2010-02-12 고쿠리츠다이가쿠호진 하마마츠이카다이가쿠 Ｅｐ４ 아고니스트를 함유하여 이루어지는 세포 상해성 ｔ 세포의 활성화제
US20080283693A1 (en) * 2007-05-15 2008-11-20 Evans Michael J F Propulsion apparatus and system
DK2441760T3 (en) 2009-06-10 2014-02-17 Ono Pharmaceutical Co A compound of bladder muscle contraction activity and activity urinrørsmuskelafslappende
JP4890657B1 (ja) * 2011-06-03 2012-03-07 小野薬品工業株式会社 リマプロストとβ−シクロデキストリンを含有する錠剤
SG2014007603A (en) 2011-08-02 2014-03-28 Ono Pharmaceutical Co Left ventricular diastolic function improving agent
SG11201501451SA (en) 2012-08-31 2015-04-29 Ono Pharmaceutical Co Amine salt and crystals thereof
PT3456710T (pt) 2016-05-09 2021-09-02 Agc Inc Novo derivado de prostaglandina
WO2023037934A1 (ja) * 2021-09-13 2023-03-16 富士フイルム株式会社 ビシクロアルカン化合物の包摂体の製造方法

Also Published As

Publication number Publication date
FR2100745B1 (xx) 1974-08-30
CH568259A5 (xx) 1975-10-31
DE2128674A1 (de) 1971-12-16
NL162901B (nl) 1980-02-15
ATA480371A (de) 1976-01-15
NO134373B (xx) 1976-06-21
HU163135B (xx) 1973-06-28
US3816393A (en) 1974-06-11
FR2100745A1 (xx) 1972-03-24
HK17577A (en) 1977-04-22
CA958007A (en) 1974-11-19
IE35326B1 (en) 1976-01-07
SU404225A3 (xx) 1973-10-26
GB1351238A (en) 1974-04-24
DK140837C (xx) 1981-09-07
BE768288A (fr) 1971-11-03
RO62182A (xx) 1977-07-15
ZA713398B (en) 1972-01-26
AT332570B (de) 1976-10-11
DE2128674C2 (de) 1982-06-24
ES392074A1 (es) 1974-08-01
JPS503362B1 (xx) 1975-02-04
NL7107894A (xx) 1971-12-14
NO134373C (xx) 1976-09-29
CY895A (en) 1977-10-07
CS170169B2 (xx) 1976-08-27
IE35326L (en) 1971-12-10
NL162901C (nl) 1980-07-15
DK140837B (da) 1979-11-26

Similar Documents

Publication Publication Date Title
SE390818B (sv) Sett att framstella klatratforeningar av prostaglandiner med cyklodextrin
NO138883C (no) Fremgangsmaate for fremstilling av oksiranforbindelser
SE402123B (sv) Sett att framstella 7-amino-3-metylcefemforeningar
SE394671B (sv) Sett att framstella gamma-piperidinobutyrofenonforeningar
SE412239B (sv) Forfarande for framstellning av 7-acylamino-cef-3-em-4-karbonsyraforeningar
SE391181B (sv) Sett att framstella kinazolinderivat
SE392103B (sv) Sett att framstella 1,2-bensisotiazolin-3-oner
SE407939B (sv) Sett att framstella 7-fluorsubstituerade fentiaziner med forlengd neurolopetisk effekt
SE385707B (sv) Sett att framstella 8,9-didehydro-10-alkoxi-ergolenderivat
SE393151B (sv) Anordning for framstellning av hopsatta profilramar
SE394281B (sv) Sett att framstella estrar av 1-metyllumilysergol-10-metyleter
SE393982B (sv) Sett att framstella dihydrokinolinderivat med antioxiderande verkan
SE373572B (sv) Forfarande for framstellning av pyroglutamyl-histidyl-prolinamid
SE381798B (sv) Forfarande for framstellning av hellbart margarin
SE382063B (sv) Sett att framstella fenyl-vinylfosfonsyraderivat
BE767528A (fr) Composes diglycidyliques durcissables
SE411759B (sv) Forfarande for framstellning av erytromycyliminforeningar
FI55639B (fi) Foerfarande foer framstaellning av en med tillsatsaemnen saerskilt eldskyddsmedel belagd fiberprodukt
FI56020C (fi) Foerfarande foer behandling av skumplastfoeremaol vilka skall foerses med ett taeckskikt av polyesterharts
SE405359B (sv) Bensisotiazolinforeningar avsedda att anvendas for framstellning av motsvarande bensisotiazolforeningar
SU437283A3 (ru) Способ получения производных пиридинкарбамата
SE394669B (sv) Sett att framstella 4-hydroxifenylglycin
SE396219B (sv) Sett att framstella pyridyl-piperazinderivat
SE385012B (sv) Sett att framstella 4,9,11 - trien-steroid-derivat
SE382810B (sv) Sett att framstella aminoisokinoliner